Evidence map›Paper›PMID 39640311›Full record

ArticleSurgical neurology international2024

Drug-resistant

Hirotaka Inoue, Jun-Ichiro Kuroda, Yutaka Fujioka, Nobuhiro Hata, Masahiro Mizoguchi, Daiki Yoshii, Hiroyuki Sueyoshi, Yuki Takeshima, Kenji Fujimoto, Naoki Shinojima and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgical neurology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hirotaka InoueDepartment of Neurosurgery, Kumamoto University Hospital, Kumamoto, Japan.
Jun-Ichiro KurodaDepartment of Neurosurgery, Kumamoto University Hospital, Kumamoto, Japan.
Yutaka FujiokaDepartment of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Nobuhiro HataDepartment of Neurosurgery, Oita University Faculty of Medicine, Yufu, Japan.
Masahiro MizoguchiDepartment of Neurosurgery, Kyushu Medical Center, Fukuoka, Japan.
Daiki YoshiiDepartment of Diagnostic Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Hiroyuki SueyoshiDepartment of Neurosurgery, Kumamoto University Hospital, Kumamoto, Japan.
Yuki TakeshimaDepartment of Neurosurgery, Kumamoto University Hospital, Kumamoto, Japan.
Kenji FujimotoDepartment of Neurosurgery, Kumamoto University Hospital, Kumamoto, Japan.
Naoki ShinojimaDepartment of Neurosurgery, Kumamoto University Hospital, Kumamoto, Japan.
Kuniko SunamiDepartment of Laboratory Medicine, National Cancer Center Hospital, Chuo-ku, Japan.
Yoshiki MikamiDepartment of Diagnostic Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Hideo NakamuraDepartment of Neurosurgery, Kurume University School of Medicine, Kurume, Japan.
Akitake MukasaDepartment of Neurosurgery, Kumamoto University Hospital, Kumamoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Combination therapy with BRAF and MEK inhibitor holds promise for treating gliomas harboring the Case Description: We describe a case of repeated recurrent Conclusion: This case study provides important insights into novel treatment strategies and their underlying mechanisms for gliomas with

Indexed as

Anaplastic pleomorphic xanthoastrocytomaBRAFDabrafenibDrug holidayTrametinib

Identifiers

PMID39640311
PMCPMC11618650

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.